Recent data from a renal cell carcinoma animal model evaluating the effect of IL-1β on immune checkpoint inhibitor resistance demonstrated the efficacy of blocking IL-1β in promoting tumor regression (20). The gene discussed is IL1B; the disease is renal cell carcinoma.